Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase I/II Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GP-2250 in Combination with Gemcitabine in Subjects with Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma Who Have Progressed on Prior Treatment with 5-Fluorouacil-based Chemotherapy
Study Type: Treatment
Phase: I/II
NCTID: NCT03854110
Principal Investigator:
Anup Kasi
A Phase 1/2 Study of M3814 Peposertib in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma
Study Type: Treatment
Phase: I/II
NCTID: NCT04172532
Principal Investigator:
Anup Kasi
Randomized Phase II Study of Platinum and Etoposide Versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas.
Study Type: Treatment
Phase: II
NCTID: NCT02595424
Principal Investigator:
Anup Kasi
A Phase II, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab IMAB362 in Combination with Nab-Paclitaxel and Gemcitabine Nab-P + GEM as First Line Treatment in Subjects with Claudin 18.2 CLDN18.2 Positive, Metastatic Pancreatic Adenocarcinoma
Study Type: Treatment
Phase: II
NCTID: NCT03816163
Principal Investigator:
Anup Kasi
GRECO-2: A Randomized, Phase II Study of Stereotactic Body Radiation Therapy SBRT in combination with GC4711 in the Treatment of Unresectable or Borderline Resectable, Nonmetastatic Pancreatic Cancer
A Phase Ib/IIa Trial Of CEND?1 In Combination With Neoadjuvant FOLFIRINOX Based Therapies In Pancreatic, Colon And Appendiceal Cancers CENDIFOX
Study Type: Treatment
Phase: I/II
NCTID: NCT05121038
Principal Investigator:
Anup Kasi
A Phase I Open Label Followed By A Phase II Randomized, Controlled Study To Assess The Efficacy And Safety Of ABTL0812 In Combination With FOLFIRINOX For First-Line Treatment Of Metastatic Pancreatic Cancer
Study Type: Treatment
Phase: I/II
NCTID: NCT04431258
Principal Investigator:
Anup Kasi
PANOVA-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields Ttfields, 150khz Concomitant with Gemcitabine and Nab-Paclitaxel for Front-Line Treatment of Locally-Advanced Pancreatic Adenocarcinoma
Study Type: Treatment
Phase: III
NCTID: NCT03377491
Principal Investigator:
Anup Kasi
A Phase I Study of Anetumab Ravtansine in Combination with Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
Study Type: Treatment
Phase: I
NCTID: NCT03816358
Principal Investigator:
Anup Kasi
Phase II Randomized Trial Combining TG01 Vaccine / QS-21 Stimulon With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer TESLA
Study Type: Treatment
Phase: II
NCTID: NCT05638698
Principal Investigator:
Anup Kasi